[go: up one dir, main page]

MX2017014075A - Composiciones de peptido y metodos de uso. - Google Patents

Composiciones de peptido y metodos de uso.

Info

Publication number
MX2017014075A
MX2017014075A MX2017014075A MX2017014075A MX2017014075A MX 2017014075 A MX2017014075 A MX 2017014075A MX 2017014075 A MX2017014075 A MX 2017014075A MX 2017014075 A MX2017014075 A MX 2017014075A MX 2017014075 A MX2017014075 A MX 2017014075A
Authority
MX
Mexico
Prior art keywords
methods
peptide compositions
portids
photoreceptors
fas
Prior art date
Application number
MX2017014075A
Other languages
English (en)
Other versions
MX387317B (es
Inventor
G Besirli Cagri
J Bridges Alexander
K Freshley John
A Hunke William
L Johnson Linda
X Smith Francis
Sylvain Ethan
N Zacks David
Original Assignee
Onl Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Onl Therapeutics Inc filed Critical Onl Therapeutics Inc
Publication of MX2017014075A publication Critical patent/MX2017014075A/es
Publication of MX387317B publication Critical patent/MX387317B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Agronomy & Crop Science (AREA)
  • Pest Control & Pesticides (AREA)
  • Plant Pathology (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Environmental Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

En la presente solicitud se proveen composiciones que incluyen póptidos, preparaciones farmacóuticas de los mismos, y métodos para prevenir muerte de fotorreceptor con las mismas y proteger las cólulas de la retina, incluyendo, pero sin limitarse a, fotorreceptores y epitelio pigmentario retiniano, contra apoptosis mediada por Fas o TRAIL.
MX2017014075A 2015-05-01 2016-04-29 Composiciones de peptido y metodos de uso. MX387317B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562155711P 2015-05-01 2015-05-01
PCT/US2016/030098 WO2016178993A1 (en) 2015-05-01 2016-04-29 Peptide compositions and methods of use

Publications (2)

Publication Number Publication Date
MX2017014075A true MX2017014075A (es) 2018-07-06
MX387317B MX387317B (es) 2025-03-18

Family

ID=57217771

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017014075A MX387317B (es) 2015-05-01 2016-04-29 Composiciones de peptido y metodos de uso.

Country Status (21)

Country Link
US (5) US10508134B2 (es)
EP (3) EP4623925A2 (es)
JP (2) JP6884755B2 (es)
KR (2) KR20240046280A (es)
CN (2) CN107708416B (es)
AU (1) AU2016258837B2 (es)
CA (1) CA2984154A1 (es)
CY (1) CY1124911T1 (es)
DK (1) DK3288379T3 (es)
EA (2) EA202090184A3 (es)
ES (1) ES2906173T3 (es)
HR (1) HRP20220138T1 (es)
HU (1) HUE057883T2 (es)
LT (1) LT3288379T (es)
MX (1) MX387317B (es)
PL (1) PL3288379T3 (es)
PT (1) PT3288379T (es)
RS (1) RS62866B1 (es)
SI (1) SI3288379T1 (es)
SM (1) SMT202200069T1 (es)
WO (1) WO2016178993A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107708416B (zh) 2015-05-01 2021-06-29 Onl医疗股份有限公司 肽组合物和使用方法
WO2019183246A1 (en) * 2018-03-20 2019-09-26 Onl Therapeutics, Inc. Compositions and methods of fas inhibition
EP3810082A1 (en) * 2018-06-19 2021-04-28 Cella Therapeutics, LLC Sustained-release drug delivery systems comprising an intraocular pressure lowering agent, a cnp compound, an npr-b compound, a tie-2 agonist, or neurotrophic agent for use for treating glaucoma or ocular hypertension
JP2023507603A (ja) * 2019-12-18 2023-02-24 セラ セラピューティクス エルエルシー 神経栄養剤、アポトーシスシグナリング断片化阻害剤（ＦＡＳ）もしくはＦＡＳリガンド（ＦＡＳＬ）阻害剤、腫瘍壊死因子α（ＴＮＦ－α）もしくはＴＮＦ受容体阻害剤、ミトコンドリアペプチド、オリゴヌクレオチド、ケモカイン阻害剤、またはシステイン－アスパラギン酸プロテアーゼ阻害剤を含む薬剤送達系
WO2022266127A1 (en) * 2021-06-15 2022-12-22 Onl Therapeutics, Inc. Methods and compositions for treating ocular disorders and diseases
WO2023287794A2 (en) * 2021-07-13 2023-01-19 Onl Therapeutics, Inc. Methods and compositions for improving visual function in ocular diseases and disorders
WO2023129766A1 (en) * 2021-12-27 2023-07-06 Onl Therapeutics, Inc. Sfasl for inhibiting rpe cell death and associated disorders
EP4565595A2 (en) * 2022-08-05 2025-06-11 ONL Therapeutics, Inc. Peptide compositions and methods of use
WO2024031024A1 (en) * 2022-08-05 2024-02-08 Onl Therapeutics, Inc. Peptide compositions and methods of use
WO2024220669A1 (en) * 2023-04-19 2024-10-24 Onl Therapeutics, Inc. Methods and compositions for treating rnfl thinning

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US5532123A (en) * 1990-07-11 1996-07-02 New York University Receptor-type phosphotyrosine phosphatase-γ
US5283185A (en) 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
JP3187201B2 (ja) * 1992-05-14 2001-07-11 三共株式会社 Ｃ末端にプロリンアミドを有するペプチドの製法
US5334761A (en) 1992-08-28 1994-08-02 Life Technologies, Inc. Cationic lipids
US5631237A (en) 1992-12-22 1997-05-20 Dzau; Victor J. Method for producing in vivo delivery of therapeutic agents via liposomes
JP3460863B2 (ja) 1993-09-17 2003-10-27 三菱電機株式会社 半導体装置の製造方法
US5714353A (en) 1994-05-24 1998-02-03 Research Corporation Technologies, Inc. Safe vectors for gene therapy
US5527928A (en) 1994-09-30 1996-06-18 Nantz; Michael H. Cationic transport reagents
US5650096A (en) 1994-12-09 1997-07-22 Genzyme Corporation Cationic amphiphiles for intracellular delivery of therapeutic molecules
US5719131A (en) 1994-12-09 1998-02-17 Genzyme Corporation Cationic amphiphiles containing dialkylamine lipophilic groups for intracellular delivery of therapeutic molecules
US5711964A (en) 1995-06-07 1998-01-27 United States Of America Method for the intracellular delivery of biomolecules using liposomes containing cationic lipids and vitamin D
US5705385A (en) 1995-06-07 1998-01-06 Inex Pharmaceuticals Corporation Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US6001962A (en) * 1996-11-15 1999-12-14 The Regents Of The University Of California Modified Fas ligands
US7091047B2 (en) * 1997-05-23 2006-08-15 A&G Pharmaceutical, Inc. Methods and kits for diagnosing tumorigenicity
US6363020B1 (en) 1999-12-06 2002-03-26 Virage Logic Corp. Architecture with multi-instance redundancy implementation
US6480428B2 (en) 2000-12-19 2002-11-12 Winbond Electronics Corporation Redundant circuit for memory device
JP2008500816A (ja) 2004-03-31 2008-01-17 ゼンコー・インコーポレイテッド 改善された性質を有するｂｍｐ−７変異体
EP1737483A2 (en) 2004-04-23 2007-01-03 University of Pittsburgh of the Commonwealth System of Higher Education Cell death modulation via antagonists of fasl and fas activation
PL1885336T3 (pl) 2005-05-10 2009-08-31 Alcon Inc Kompozycja w postaci zawiesiny zawierająca substancję aktywną, poloksamerowy lub meroksapolowy surfaktant i glikol oraz zastosowanie kompozycji do wytwarzania leku do leczenia chorób oczu
KR20080065704A (ko) * 2005-11-09 2008-07-14 콤비네이토릭스, 인코포레이티드 의학적 이상의 치료 방법들, 조성물들, 및 키트들
CA2631731A1 (en) * 2005-12-01 2007-06-07 University Of Pittsburgh Of The Commonwealth System Of Higher Education Compounds and methods for inhibiting apoptosis
AU2008345689B2 (en) * 2007-12-21 2013-04-18 Stryker Corporation BMP mutants with decreased susceptibility to Noggin
US8343931B2 (en) * 2009-03-03 2013-01-01 The Regents Of The University Of Michigan Methods of inhibiting photoreceptor apoptosis
CA2756864A1 (en) * 2009-03-30 2010-10-07 Santen Pharmaceutical Co., Ltd. Prophylactic or therapeutic agent for retinal disease and method for prophylaxis or therapy of retinal disease using jnk (c-jun amino-terminal kinase)-inhibitory peptide, and use of the peptide
EP2462128B1 (en) * 2009-08-04 2016-09-21 Amira Pharmaceuticals, Inc. Compounds as lysophosphatidic acid receptor antagonists
BR112013021494B1 (pt) 2011-02-22 2021-09-08 California Institute Of Technology Vetor viral, polinucleotídeo isolado, uso de um vírus adeno-associado (aav) recombinante e método para produzir o mesmo
JP6250536B2 (ja) * 2011-06-06 2017-12-20 ケイ・ブイ・１．３・セラピューティクス・インコーポレイテッド Ｓｈｋベースの薬学的組成物とその製造方法および使用方法
US9428550B2 (en) 2012-01-18 2016-08-30 Governing Council Of The University Of Toronto Peptides and methods and uses thereof for preventing retinal disorders
BR112014031923B1 (pt) * 2012-06-21 2022-02-08 Daewoong Pharmaceutical Co., Ltd. Uso de uma composição compreendendo pelo menos um tnfri modificado ou fragmento tnfri modificado, uso de uma formulação tópica e uso de uma composição
CA2890238A1 (en) * 2012-11-02 2014-05-08 Merck Patent Gmbh Method of reducing adverse effects in a cancer patient undergoing treatment with a mek inhibitor
WO2016125148A1 (en) 2015-02-05 2016-08-11 Immunarray Ltd. Methods and compositions for diagnosing brain injury or neurodegeneration
CN107708416B (zh) * 2015-05-01 2021-06-29 Onl医疗股份有限公司 肽组合物和使用方法
US20190201500A1 (en) 2015-05-01 2019-07-04 Onl Therapeutics, Inc. Compositions and methods of fas inhibition
CN110177577A (zh) 2016-07-05 2019-08-27 马萨诸塞大学 Sfasl的aav2介导的基因递送作为青光眼的神经保护疗法
AU2018290228B2 (en) 2017-06-21 2021-07-01 Gilead Sciences, Inc. Multispecific antibodies that target HIV gp120 and CD3
WO2019183246A1 (en) 2018-03-20 2019-09-26 Onl Therapeutics, Inc. Compositions and methods of fas inhibition
EP3810082A1 (en) 2018-06-19 2021-04-28 Cella Therapeutics, LLC Sustained-release drug delivery systems comprising an intraocular pressure lowering agent, a cnp compound, an npr-b compound, a tie-2 agonist, or neurotrophic agent for use for treating glaucoma or ocular hypertension

Also Published As

Publication number Publication date
KR20240046280A (ko) 2024-04-08
EP3288379A4 (en) 2018-10-24
US12258425B2 (en) 2025-03-25
CN113651873B (zh) 2025-09-02
CN107708416A (zh) 2018-02-16
HUE057883T2 (hu) 2022-06-28
EP3997981A1 (en) 2022-05-18
US10829518B2 (en) 2020-11-10
SMT202200069T1 (it) 2022-03-21
RS62866B1 (sr) 2022-02-28
HK1251979A1 (zh) 2019-05-10
CA2984154A1 (en) 2016-11-10
AU2016258837B2 (en) 2020-12-03
BR112017023479A2 (pt) 2018-07-24
CY1124911T1 (el) 2023-01-05
EP4623925A2 (en) 2025-10-01
HRP20220138T1 (hr) 2022-05-27
US20210094985A1 (en) 2021-04-01
JP6884755B2 (ja) 2021-06-09
US20250346631A1 (en) 2025-11-13
EA202090184A2 (ru) 2020-05-31
PL3288379T3 (pl) 2022-03-07
CN107708416B (zh) 2021-06-29
PT3288379T (pt) 2022-02-08
EA202090184A3 (ru) 2020-07-31
JP2021120400A (ja) 2021-08-19
MX387317B (es) 2025-03-18
US11597749B2 (en) 2023-03-07
US20230287052A1 (en) 2023-09-14
EP3288379A1 (en) 2018-03-07
US20180291062A1 (en) 2018-10-11
EP3288379B1 (en) 2021-11-03
AU2016258837A1 (en) 2017-11-09
SI3288379T1 (sl) 2022-06-30
EA201792399A1 (ru) 2018-05-31
KR20170140383A (ko) 2017-12-20
JP2018514590A (ja) 2018-06-07
LT3288379T (lt) 2022-02-25
CN113651873A (zh) 2021-11-16
US20200123201A1 (en) 2020-04-23
WO2016178993A1 (en) 2016-11-10
ES2906173T3 (es) 2022-04-13
KR102652804B1 (ko) 2024-04-01
EA035293B1 (ru) 2020-05-26
DK3288379T3 (da) 2022-02-07
US10508134B2 (en) 2019-12-17

Similar Documents

Publication Publication Date Title
MX2017014075A (es) Composiciones de peptido y metodos de uso.
CL2018003142A1 (es) Moduladores de la vía de estrés integrada
MX2018014869A (es) Composiciones y metodos de uso en nintedanib para tratar enfermedades oculares con neovascularizacion anormal.
NI201500131A (es) Virus de la enfermedad de newcastle y usos de los mismos
BR112018012707A2 (pt) inibidores da interação de menin-mll
PE20190563A1 (es) Genes de mini-distrofina optimizados y casetes de expresion y su uso
BR112017008198A2 (pt) pró-fármacos de carbidopa e l-dopa e métodos de uso
MX2017016655A (es) Formulaciones oftalmicas de inhibidores de tirosina quinasa, metodos de uso de las mismas y metodos de preparacion de las mismas.
MX2017001512A (es) Compuestos activos hacia bromodominios.
DOP2015000246A (es) Derivados de oxopiridina sustituida y usos de los mismos en el tratamiento de trastornos cardiovasculares
EA201691582A1 (ru) Новые фармацевтические препараты
MX369041B (es) Proteinas quimericas tipo fosfatasa alcalina.
UY36224A (es) Compuestos tricíclicos de imidazo-pirimidinona
MX2019001877A (es) Composiciones farmaceuticas oftalmicas y usos que se relacionan a las mismas.
MX378108B (es) Anticuerpos anti-met y composiciones.
MX2016011176A (es) Polipeptidos fhbp meningococicos modificados.
MX2018012285A (es) Metodos de tratamiento para enfermedades colestasicas y fibroticas.
EP3280498A4 (en) Protective action of lutein against blue light on human skin cell lines
BR112017015159A2 (pt) preparação e uso de produtos plaquetários
IL254617A0 (en) Improved assays for the potential of retinal pigment epithelium (rpe) cells and photoreceptor progenitors
CL2020000056A1 (es) Nuevos derivados de xantina sustituidos.
EP3193867A4 (en) Ocular formulations for drug-delivery and protection of the anterior segment of the eye
MX2017001396A (es) Metodos para mejorar el rendimiento miocardico en pacientes con cirugia de fontan que utilizan composiciones de udenafilo.
PE20160596A1 (es) Formulacion de atazanavir y cobicistat para el tratamiento del virus de inmunodeficiencia humana
TWD181311S (zh) 安全護目鏡